

Detroit Wayne Integrated Health Network

707 W. Milwaukee St. Detroit, MI 48202-2943 Phone: (313) 833-2500 www.dwihn.org

FAX: (313) 833-2156 TDD: (800) 630-1044 RR/TDD: (888) 339-5588

BULLETIN NUMBER:	23-006
ISSUED/REVISED:	01/01/2023
EFFECTIVE:	10/01/2022
SUBJECT:	Injection, Buprenorphine, Extended release (XR) - Sublocade
SERVICE AFFECTED:	Q9991 – Buprenorphine XR less than or equal to 100mg Q9992 – Buprenorphine XR greater than 100mg

BACKGROUND

To assist our efforts to treat opioid use disorders, DWIHN will include Buprenorphine Extended Release Sublocade injectable to the service array of Medication Assisted Treatment (MAT) providers. In order to report the administration of Buprenorphine Extended Release Sublocade injectable in a SUD MAT setting, DWIHN has identified procedure codes Q9991 and Q9992. Procedure codes Q9991 and Q9992 will be deployed, effective 08-01-2022, to the Substance Use Disorder contracts for the various SUD MAT program providers. This code must be reported along with the required modifiers (see Chart, below). Note: Administration of injectable medications (96372) is not reported Q9991 or Q9992, it is reported with other CPT codes.

PROCEDURE

CRITERIA FOR USE: Prior Authorization by the Utilization Management Department for Sublocade (buprenorphine Extended Release injection) will be considered medically necessary when ALL of the following criteria are met:

- Medical record documentation that the patient is 18 years of age or older AND
- Medical record documentation of a diagnosis of opioid use disorder (opioid dependence) AND
- Medical record documentation that member has been initiated into treatment with a transmucosal buprenorphine containing product (e.g. Suboxone, buprenorphine/naloxone, buprenorphine), followed by dose adjustment for a minimum of 7 days AND until cravings and withdrawal symptoms are clinically controlled AND
- Medical record documentation that the member will not be receiving supplemental sublingual buprenorphine concurrently with Sublocade AND
- Confirmation that the prescriber or prescriber's delegate has conducted a review of Michigan's Prescription Drug Monitoring Program (PA PDMP) prior to administering Sublocade.
- AUTHORIZATION DURATION: If approved, initial authorization duration will be for 3 months. After the initial 3-month authorization, subsequent approval will be for 12 months or less if *the*

reviewing provider feels it is medically appropriate and will require medical record documentation of the following:

- Medical record documentation that the member will not be receiving supplemental sublingual buprenorphine concurrently with Sublocade AND
- Medical record documentation of one of the following: That the member will continue to receive the 100mg monthly maintenance dose.

Counseling

- The member is part of a complete treatment program that includes counseling and other supports.
- Member is responding positively to therapy

AUTHORIZATIONS: Three (3) encounters per month.

CLAIMS: Claims must be submitted with the MDHHS required Education-level modifier listed below, as appropriate. The appropriate NDC code is also required on claims. The rate includes cost of medication administration and observation.

Procedure Code	Modifiers	Description
Q9991 - Buprenorphine	AF – Specialty Physician (Psychiatrist)	
XR, less than or equal to	AG – Physician	Injection,
100mg	HM – Less than Bachelor's Level	Buprenorphine
	SA – Licensed Physician Assistant	extended-
Q9992 - Buprenorphine	SA – Nurse Practitioner	release
XR, greater than 100mg	SA – Clinical Nurse Specialist	(Sublocade)
	TD – Registered Nurse	
	TE – Licensed Practical Nurse	

CHART: Administration of Buprenorphine Extended Release Sublocade injectable

REFERENCES:

Michigan Medicaid Provider Manual http://www.michigan.gov/mdhhs/0,5885,7-339-71551 2945 42542 42543 42546 42553-87572--,00.html

MDHHS Website: PIHP/CMHSP Reporting Cost Per Code and Code Chart https://www.michigan.gov/mdhhs/0,5885,7-339-71550_2941_38765---,00.html

MDHHS Website: PIHP/CMHSP Provider Qualifications Chart https://www.michigan.gov/mdhhs/0,5885,7-339-71550_2941_38765---,00.html